Proceeds will be used to enable key late-stage clinical trial readouts for assets across several underserved neurological diseases with high unmet medical need.

EQT Life Sciences has led the extension, and joins a consortium of prominent global biotechnology investors.

The investment builds on EQT Life Sciences’ previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo, MD

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Noema Pharma (“the Company”). The clinical-stage biotech company headquartered in Basel, Switzerland is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series B extension brings the total capital raised in the round to CHF 130 million, including prior investments from Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

CNS disorders are a significant area of unmet medical need, affecting hundreds of millions of people worldwide who often face inadequate treatment options with limited effectiveness and significant side effects. Many of the conditions targeted by Noema Pharma have historically been difficult to treat due to their complex nature and the lack of effective therapies. By leveraging its diverse portfolio of neurological assets and innovative clinical pipeline, Noema Pharma is strongly positioned to address these debilitating disorders and provide much-needed hope and transformative solutions to patients living with these life-altering challenges. The Company’s portfolio includes four active Phase 2 trials, with key readouts from all studies anticipated in 2025.

Proceeds from the financing will drive the continued development of Noema Pharma’s clinical-stage assets, including its lead candidate basimglurant (NOE-101), a mGluR5 inhibitor currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC). Additionally, the Company is advancing gemlapodect (NOE-105), a PDE10a inhibitor in Phase 2 for Tourette syndrome and childhood onset fluency disorder (COFD or stuttering), as well as NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and additional symptoms of menopause.

Ilise Lombardo, MD, CEO of Noema Pharma, stated: “We are thrilled to welcome EQT Life Sciences as a lead investor and to have Felice join our Board. Their support and expertise will be invaluable as we progress our clinical programs and strive to make a meaningful impact on patients’ lives.”

Felice Verduyn-van Weegen, Partner at EQT who is joining the Company’s Board of Directors, commented: “Noema Pharma’s innovative approach to CNS disorders aligns very well with our investment strategy and we are excited to support their late-stage clinical pipeline and transformative therapies. Having worked with Ilise Lombardo on a previous successful investment, her exceptional leadership as a repeat entrepreneur further reinforces our confidence in Noema’s potential to deliver meaningful impact to patients in need.”

Contact
EQT Press Office, press@eqtpartners.com

Irish maternal health company Nua Surgical secures €6.5M in Series A funding led by EQT Life Sciences

SteriCISION is the first self-retaining retractor designed specifically for Caesarean section (C-section) surgeries

Proceeds will be used for regulatory approval and commercialization of the SteriCISION C-section retractor

EQT Life Sciences is pleased to announce that the EQT Health Economics strategy has invested in Nua Surgical, an Irish medical device company innovating in maternal health. The €6.5 million Series A financing was led by EQT Life Sciences. The round was also supported by new investors Kidron Capital and the Texas Medical Center (TMC) Venture Fund and existing investors including Enterprise Ireland and business veterans from Ireland and the US. The proceeds will be used to drive the regulatory clearance and early commercialization of the company product, the SteriCISION C-Section Retractor. This innovative device is specifically designed to address the unique challenges of Caesarean-section (C-section) surgery.

C-sections are the most common major surgical procedure globally, with over 30 million performed each year. The SteriCISION C-Section Retractor is the only self-retaining surgical retractor specifically designed for the unique dynamics of C-section surgery. This ergonomically designed and patented device provides fast, adjustable, and safe retraction, enabling clinicians to deliver the baby, repair tissue, and, crucially, identify bleeds. As a single-use sterile device, it aims to reduce the risk factors that lead to surgical complications, benefiting the patient, the clinician, and the healthcare system. The new investment will support Nua Surgical’s next phase of development and the early commercialization of SteriCISION. This includes expanding the team, establishing manufacturing in Ireland, and meeting the regulatory requirements necessary to gain FDA clearance.

Barry McCann, CEO of Nua Surgical, commented, “Securing this Series A financing is a crucial milestone for Nua Surgical. It not only provides the capital needed to advance our product but also brings on board a group of experienced investors who share our vision for transforming maternal health. We are eager to leverage their expertise as we move towards commercializing SteriCISION.”

“Nua Surgical’s SteriCISION C-Section Retractor has the potential to significantly enhance outcomes for mothers undergoing C-section procedures,” said Anne Portwich, Partner at EQT. “We are excited to support the company’s journey towards market entry. This innovative device has the potential to improve the quality of care and reduce healthcare costs, making it a perfect fit for our EQT Health Economics strategy.”

With the closure of this round, Anne Portwich, Partner at EQT, and Anula Jayasuriya, Co-Founder of Kidron Capital, will join the Nua Surgical Board of Directors, while Gabrielle Guttman of TMC Venture Fund and Prashanthi Ramesh of EQT will serve as Board Observers.

Contact
EQT Press Office, press@eqtpartners.com

About

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs entrepreneurs who have ideas that could truly make a difference for patients. The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that entrepreneurs seek. For more information, go to eqtgroup.com/private-capital/life-sciences/

About Nua Surgical
Nua Surgical is a Galway-based medical company founded in 2019 by Barry McCann, Marie-Therese Maher and Padraig Maher. Since spinning out of the renowned BioInnovate Ireland programme at the University of Galway, Nua Surgical have become an Enterprise Ireland HPSU company and have received global accolades for their maternal health innovation. The company has developed the SteriCISION C-section Retractor, ergonomically designed to improve access and visualization to the uterus, reduce the risk of wound trauma and facilitate a safer surgery. The experienced founding team is bolstered with expert consultants and the recent appointment of Dr. Elizabeth Garner, global women’s health thought leader, as their board chair. For more information visit www.nuasurgical.com

A leader in medical device manufacturing, TEAM Tech is focused on optimizing supply chains to ensure better and faster delivery of critical healthcare products

Washington, D.C. – November 25, 2024 – Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced it has acquired TEAM Technologies, Inc (“TEAM Tech”), a leading global manufacturer of essential healthcare products, from Clearlake Capital Group (“Clearlake”).

TEAM Technologies is a leading provider of specialized manufacturing and strategic supply chain solutions to blue-chip healthcare customers. The Company provides a broad array of end-to-end outsourced design and manufacturing services to medical device and pharmaceutical OEMs, with a growing specialty in advanced medical devices that are critical to the healthcare system. Through its comprehensive suite of vertically integrated processes, TEAM Tech enables customers to streamline their supply chains and reduce lead times in delivering critical products. TEAM Tech has approximately 1,000,000 square feet of manufacturing space across nine campuses in the U.S., Mexico, and Singapore.

“As the last five years have demonstrated, global supply chains are not nearly as fortified as they need to be, particularly in medical device manufacturing,” said Matt Altman, a Managing Partner at Arlington Capital Partners. “TEAM Tech is not only focused on providing the world’s leading healthcare OEMs with holistic solutions for all their design and manufacturing needs, but also on strengthening our healthcare supply chains to improve the delivery of these critical goods to end users.” Added Gordon Auduong, an Arlington Principal, “As one of the leading end-to-end providers in this sector, we look forward to working with TEAM Tech’s management team and building on its strong foundation to continue adding capabilities and customers, both through organic investment and strategic acquisitions.”

“The medical device manufacturing industry is incredibly complex, but we feel fortunate to partner with Arlington in our next chapter,” said Marshall White, CEO of TEAM Tech. “I have gotten to know Matt and the Arlington team well over the past several years and believe that with their 25 years of experience in this highly regulated sector they are best positioned to help us build on the successes we have achieved and accelerate our growth, both organically and through strategic acquisitions, to take our business to the next level.”

Arlington has an extensive track record of building leading companies in the highly regulated healthcare sector, focusing on businesses that save lives, improve the delivery of products and services, and reduce costs for patients and providers. Recent investments include Afton Scientific, AVS Bio, Millstone Medical Outsourcing, Riverpoint Medical and Grand River Aseptic Manufacturing.

Harris Williams served as financial advisor and Goodwin Procter LLP served as legal advisor to Arlington Capital Partners. R.W. Baird acted as financial advisor to TEAM Technologies. Kirkland & Ellis LLP and Massumi + Consoli provided legal counsel to TEAM Technologies and Clearlake.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. The firm partners with founders and management teams to build strategically important businesses in the healthcare, government services & technology, and aerospace & defense sectors. Since its inception in 1999, Arlington has invested in over 175 companies and is currently investing out of its $3.8 billion Fund VI. For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn.

About TEAM Tech

Headquartered in Morristown, TN, TEAM Technologies is a specialized end-to-end outsourced manufacturer of mission-critical medical devices. The Company has an extensive array of advanced and vertically integrated manufacturing solutions servicing top medical device and pharmaceutical OEMs. With its deep industry experience and reputation for the highest quality standards, TEAM Technologies leverages seamless, turnkey processes and innovation to drastically simplify its customers’ supply chains. For more information, visit teamtech.com.

rehaneo, a leading provider of outpatient rehabilitation, aftercare, prevention, and occupational health management founded in 2020, welcomes Fremman Capital to its shareholder base. Fremman takes over the majority shareholding previously held by the European investment company Gimv. Founder and CEO Bruno Crone and co-founder and COO Christoph Dühr remain significantly invested in the company and continue their management roles.

Since its founding four years ago, during the peak of the COVID-19 pandemic, Gimv and the managing rehaneo shareholders Bruno Crone and Christoph Dühr have successfully built the company into one of the top three providers in the field of outpatient rehabilitation through a successful buy-and-build strategy. Since 2023, Dr. Alain Robbe-Grillet completes the management team as CFO.

To date, rehaneo has integrated 13 companies at 23 locations nationwide into the group, including some of the leading facilities in Germany. Recently, rehaneo also opened a completely new center in Göttingen.

The rehaneo group now employs over 1,000 staff who are dedicated to the care of more than 80,000 patients and customers annually. The range of services offered by the centers varies by location, from outpatient rehabilitation and rehab aftercare to physiotherapy and occupational therapy, as well as prevention and fitness. In addition to developing locations and the continuous growth of the group, the focus is primarily on the quality of services. This is ensured, among other things, by a medical board with renowned experts, including Prof. Dr. med. Thomas Wessinghage. rehaneo aims to further densify the care network and offer more people professional rehabilitation close to their homes.

Outpatient rehabilitation costs are significantly lower than inpatient stays, benefiting the healthcare system. Additionally, there is increasing demand from patients who want to stay in their familiar environment during rehabilitation. Together with Fremman, the management team intends to continue the successful growth strategy, accelerating M&A and consolidating further a very fragmented sector, to create a European leader.

Bruno Crone, Founder and CEO of the rehaneo group, declares: “We thank Gimv for their active support and the trustful cooperation from the beginning, which made it possible to become one of the leading quality providers in outpatient rehabilitation in such a short time. We are excited to start a new chapter of our success story with Fremman. Our focus will be on acquiring new outpatient rehab centers and the strategic development of existing facilities and the entire group.”

Mirko Meyer-Schönherr and Max Schürenkrämer, Founding Partner and Managing Director at Fremman, add: “We are very impressed by the development of the rehaneo group so far and see great potential in the outpatient rehabilitation sector. We look forward to supporting the experienced and ambitious rehaneo management team in further developing the strategy of the group.”

Philipp von Hammerstein and Lars Timmer, Partner and Principal at Gimv Healthcare, comment: “We are proud that together with rehaneo, we have built a leading company and competent partner in outpatient care in just four years, distinguished by high customer and patient satisfaction as well as high-quality standards.”

The transaction is subject to approval by the German antitrust authorities and is expected to close in Q1 2025. This transaction will have a positive impact on our NAV at 30 September 2024, as will be published on 21 November next, of around EUR 1 per share. The realized return on this transaction substantially exceeds our long-term portfolio return target.

Deventer, November 19, 2024 – 819 Capital Partners and LIOF have invested in I-Med Technology (“I-Med”) in a substantial investment round. I-Med Technology develops and markets advanced head-mounted 3D imaging systems that provide real-time support, enhancing precision and efficiency in medical and dental procedures.

I-Med secures strategic investment to fuel 3D imaging expansion

I-Med Technology B.V., a cutting-edge medical technology company specializing in advanced 3D imaging systems for healthcare, announced today that it has secured an investment from 819 Capital Partners and LIOF, positioning the company for rapid growth and expanded market impact. Johan van de Ven, CEO of I-Med: “We are thrilled to partner with 819 Capital Partners and LIOF. Their support and investment enable us to move swiftly in bringing our technology to more clinicians and expanding our reach in the medical imaging market. This funding underscores the value of our innovation and allows us to continue pushing boundaries in medical visualization technology.”

Revolutionizing surgery: I-Med’s 3D head-mounted microscope enhances precision and safety

Founded in 2018 and headquartered at the Brightlands Health Campus in Maastricht, I-Med is committed to addressing critical challenges in surgical and dental procedures where precision and speed are essential. Vincent Graham, CTO at I-Med: “Traditional 2D imaging techniques, often displayed away from the surgical field, require clinicians to shift focus frequently, impacting procedural efficiency. I-Med’s Digital Head-mounted Microscope offers a breakthrough solution with Full HD, real-time 3D imaging, mixed realities, enhancing precision and quality while providing a safer and more seamless operating experience.” Jaap Heukelom, CCO at i-Med Technology, adds: “Moreover, the system represents a leap forward for medical training, education and remote support applications and offers a powerful platform for artificial intelligence applications that can assist the surgeon and dentist alike in their clinical practice”.

Investment driving societal impact in healthcare through improved patient outcomes

819 Capital Partners has invested in I-Med through 819 Evergreen Fund I, a fund committed to investments in deep-tech and med-tech ventures. Sven Kempers, director at 819: “Our investment in I-Med aligns with our goal of advancing promising technology. We have great confidence in I-Med’s technology and its growth potential.”

LIOF has invested in I-Med from their Participation Fund, a fund committed for newly started and medium-sized, innovative SMEs who want to grow. Willem van Esch, investment manager at LIOF: “We see the potential in I-Med’s 3D imaging systems to redefine surgical precision and enhance patient care. Our support will help accelerate their impact across the healthcare sector, making advanced imaging more accessible and transforming the future of medical procedures.”

About I-Med Technology B.V.

I-Med Technology B.V. is a medical technology company based in Maastricht dedicated to advancing real-time, mixed realities, 3D imaging solutions through head-mounted systems designed to support precise medical and dental interventions. With its unique, MDD and CE certified, DHM platform, I-Med empowers healthcare professionals with enhanced visualization capabilities that promote improved procedural outcomes and patient care. More information: www.i-medtech.nl

About 819 Capital Partners

819 Capital Partners is an investment firm managing multiple funds with targeted investment strategies. 819 Evergreen Fund takes minority stakes in early-stage deep-tech and med-tech startups, while 819 Private Equity Fund acquires controlling stakes in mature firms within the leisure, IT, and healthcare industries. The open-ended structure of their funds allows for long-term investments with flexible exit timelines. The firm focuses on sectors like healthcare, technology, and leisure, addressing societal challenges such as aging populations.

About LIOF

LIOF is the regional development agency for Limburg and supports innovative entrepreneurs with advice, network and financing. LIOF is available for every start-up, scale-up and small and medium-sized business (SME) with an innovative idea, a business plan or a financing request and for (foreign) entrepreneurs who want to establish themselves in Limburg. LIOF also helps with cross-border cooperation and international trade. Together with entrepreneurs and partners, LIOF is working towards a smarter, more sustainable and healthier Limburg by focusing on the transitions energy, circularity, health and digitalization.

NEW YORK & AUCKLAND, NEW ZEALAND – November 19, 2024 – Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced that it has completed its acquisition of Arvida Group Limited (“Arvida” or the “Company”) (NZX: ARV), one of New Zealand’s largest retirement and aged care providers.

“As one of the leading and most well-regarded retirement village operators in New Zealand, we believe Arvida has a bright future ahead and is well positioned to effectively serve the region’s growing aging population as a privately held entity,” said Darren Keogh, Senior Managing Director at Stonepeak. “We are excited to have closed this transaction and look forward to partnering closely with the Arvida team as the company enters this next chapter.”

“Today marks a transformational day for Arvida, and I am optimistic about the opportunities ahead,” said Jeremy Nicoll, Chief Executive at Arvida. “Stonepeak is aligned with our values and commitment to our employees, residents, and community, and we look forward to leveraging their extensive operational expertise as we execute on our strategy and mission of helping New Zealanders live a truly fulfilling life as they age.”

About Stonepeak

Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately $70 billion of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, with a focus on downside protection and strong risk-adjusted returns. Stonepeak, as sponsor of private equity and credit investment vehicles, provides capital, operational support, and committed partnership to grow investments in its target sectors, which include communications, energy and energy transition, transport and logistics, and real estate. Stonepeak is headquartered in New York with offices in Houston, London, Hong Kong, Seoul, Singapore, Sydney, Tokyo, and Abu Dhabi. For more information, please visit www.stonepeak.com.

About Arvida

Arvida is one of New Zealand’s largest aged care providers owning and operating 35 retirement villages located nationally. Each village operates independently under a corporate structure that supports village operations to ensure quality and consistency of service. Arvida provides a range of living and lifestyle options from independent living to full rest home, hospital and dementia-level care.

Arvida’s growth strategy includes the targeted development of new villages in areas that are supported by a strong demographic and economic profile and acquisition of quality villages that meet strict acquisition criteria as well as the development of additional facilities at existing villages.

Website: www.arvida.co.nz

Contacts

Stonepeak
Kate Beers / Maya Brounstein
corporatecomms@stonepeak.com
+1 (646) 540-5225

Jack Gordon
jack.gordon@sodali.com
+61 478 060 362

Arvida
Geoff Senescall, Senescall Akers
senescall@senescallakers.co.nz
+64 21 481 234

Blue Earth Capital (“BlueEarth”), a global specialist impact investor, today announces an $ 11 million private credit commitment to Rhino Park Holdings (Proprietary) Limited (“Rhino Park”), a leading multi-disciplinary private hospital in Namibia specializing in maternity and neonatal healthcare.

The investment marks BlueEarth’s first private credit investment in the healthcare sector, and the issuance of its second sustainability-linked loan. BlueEarth’s investment supports the acquisition of the hospital by Salt Capital, a Southern Africa focused private equity investment manager. The funding will work to catalyze Rhino Park’s ambitious expansion plans, including the development of a best-in-class operating theatre for more advanced surgical procedures, an innovative primary healthcare center, and new MRI imaging facilities.

The maternal mortality rate is one of Namibia’s most pressing healthcare concerns, ranking second highest among upper-middle-income countries globally.¹³  In addition, neonatal disorders are a leading cause of premature death in Namibia, with 32% of under-five deaths occurring in the first month of life.¹⁴ As Namibia’s second-largest private hospital with a world-class obstetrics department – the nation’s largest – Rhino Park is at the forefront of addressing these critical healthcare challenges in the country.

Beyond immediate patient care, Rhino Park demonstrates its commitment to furthering the nation’s healthcare development by offering nursing student placement programs and providing study loans to its nursing staff. This further upskills workers, ensuring continuity to Namibia’s ability to produce an adequate supply of skilled domestic health workers.

These factors, combined with the sustainability and impact-linked characteristics of the facility, (BlueEarth’s second such loan), work to ensure full alignment with BlueEarth’s dual mission of generating compelling social impact alongside financial returns, and represents a significant step in advancing healthcare accessibility and quality in Southern Africa.

Amy Wang, Head of Private Credit at BlueEarth, comments: “This partnership with Salt Capital represents a wonderful opportunity to transform healthcare delivery in Namibia. By investing into Rhino Park’s growth, we are not just expanding a leading medical center but also helping to build a healthier future for Namibians. We hope that this investment will help provide high-quality healthcare to an increasing number of patients and support the steady improvement of overall health outcomes. Healthcare has long been a priority vertical impact at Blue Earth Capital, and we are very excited to complete our investment alongside these trusted partners. We are also particularly proud to continue driving forward the practice of linking impact with financial return with our second sustainability-linked loan.”

Martin van Niekerk, CEO of Rhino Park, comments: “We are thrilled for the support received from BlueEarth, which will allow us to embark on an ambitious expansion plan that will significantly enhance our healthcare offerings. This funding will allow us to expand our facilities, invest in advanced medical technologies, and increase our capacity to serve our community. Our commitment to providing exceptional, caring, dignified, and affordable patient care to the people of Namibia remains unwavering, and this expansion will position us to better meet the growing needs of our patients and families in the years to come.’’

Jan Bosch, Managing Partner at Salt Capital, comments: “Today marks an exciting milestone for our firm as we close this transaction, bringing together a shared vision and complementary strengths of Salt Capital and the management team of Rhino Park hospital to create lasting value. This achievement is a testament to the hard work and dedication of our team, our partners, and all those who contributed to making this deal possible. We extend our sincere gratitude to our debt funding partners, Blue Earth Capital, for their invaluable support and confidence, which played a crucial role in bringing this vision to life. We look forward to supporting Rhino Park to continue on its journey of growth and service to the community and are confident in our ability to drive meaningful impact and deliver strong returns for all our stakeholders.’’

 -END-

 Note to editors

About Blue Earth Capital
Blue Earth Capital is a global, independent, specialist impact investor, headquartered in Switzerland, with operations in New York, London, and Konstanz. Blue Earth Capital seeks to address the world’s most pressing social and environmental challenges by delivering measurable impact alongside aiming for attractive and market-rate financial returns. The company operates dedicated private equity, private credit, and fund solutions as well as separately managed accounts. Blue Earth Capital is owned by the Blue Earth Foundation, a Stiftung (charity/trust) registered in Switzerland that focuses on deep impact to support initiatives and business ventures to help deliver a more equitable and sustainable future.

About Rhino Park
Rhino Park is a leading multi-disciplinary private hospital in Namibia with a specialty in maternity and neonatal healthcare. Founded over 30 years ago in 1994, the hospital started out as a day hospital and has since grown to become the joint second largest private hospital in the country with the largest obstetrics department in the country, whilst also being the first hospital to have established one of only two pediatric ICUs in Namibia.

About Salt Capital
Founded in 2012, Salt Capital is a private equity fund manager focused on SME growth capital investments in the sub-Saharan Africa. Based in London and Johannesburg, Salt Capital’s four Partners have built a track record of successful private equity investments with a core focus on the African consumer.

Blue Earth Capital media contact:
Kekst CNC
Blueearthcapital@kekstcnc.com